

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50304/091001
	Serial No.	10/542,238
	Applicant	FRESON et al.
	Filing Date	July 15, 2005
	Group	To Be Assigned
	IDS Filed	August 30, 2005

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 01/23420	04/05/01	PCT			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
/MS/	Cox et al., "VIP Elevates Platelet Cyclic AMP (cAMP) Levels and Inhibits In Vitro Platelet Activation Induced By Platelet-Activating Factor (PAF)," <i>Peptides</i> , 5:325-328 (1984).					
	Freson et al., "The Pituitary Adenylate Cyclase-Activating Polypeptide Is a Physiological Inhibitor of Platelet Activation," <i>The Journal of Clinical Investigation</i> , 113:905-912 (2004).					
	International Search Report (PCT/EP2004/001209)					
	Written Opinion of ISA (PCT/EP2004/001209)					
/MS/	International Preliminary Report on Patentability (PCT/EP2004/001209)					

EXAMINER	/Michael Szperka/	DATE CONSIDERED	06/30/2008
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			